Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Nervous System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Nervous System Neoplasm

Cancer Family

Nervous System Neoplasm

CI-CAN-00000038Explore in graph →

Non-malignant1,523 active trials9 approved drugs210 evidence items

NCIt: C3268
MeSH: D009423

Overview
Statistics
Survival
Genomics48
Variants & evidence210
Drugs47
Trials5871
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (168)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 76–100 of 168 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
· J Clin Oncol · 2015 · PMID 26169613 · validated civic_curation pubmed
Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
· Oncotarget · 2016 · PMID 26894859 · validated civic_curation pubmed
Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
· Anticancer Res · 2011 · PMID 22199315 · validated civic_curation pubmed
Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
· Cancer · 2006 · PMID 16541434 · validated civic_curation pubmed
Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.
· Science · 2013 · PMID 23539183 · validated civic_curation pubmed
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
· J Clin Oncol · 2010 · PMID 20713864 · validated civic_curation pubmed
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
· J Clin Oncol · 2016 · PMID 27001570

Showing 76–100 of 168 publications

← Previous
1
2
3
4
5
6
7
Next →

· validated civic_curation

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.

· Cold Spring Harb Mol Case Stud · 2018 · PMID 29907598 · validated civic_curation pubmed

Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an NTRK2 Fusion: The Impact of Integrated Genomic Profiling.

· JCO Precis Oncol · 2021 · PMID 34651095 · validated civic_curation pubmed

A Unique Case Report of Infant-Type Hemispheric Glioma (Gliosarcoma Subtype) with TPR-NTRK1 Fusion Treated with Larotrectinib.

· Pathobiology · 2022 · PMID 35034013 · validated civic_curation pubmed

Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome.

· Brain Pathol · 2017 · PMID 27380723 · validated civic_curation pubmed

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

· Science · 2009 · PMID 19726788 · validated civic_curation pubmed

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.

· J Clin Oncol · 2012 · PMID 22162573 · validated civic_curation pubmed

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.

· Cancer Discov · 2016 · PMID 27683556 · validated civic_curation pubmed

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.

· J Transl Med · 2014 · PMID 25524464 · validated civic_curation pubmed

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.

· Oncologist · 2020 · PMID 32043779 · validated civic_curation pubmed

Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation.

· Cold Spring Harb Mol Case Stud · 2021 · PMID 33637608 · validated civic_curation pubmed

Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation.

· JCO Precis Oncol · 2022 · PMID 35507888 · validated civic_curation pubmed

Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion.

· Oncologist · 2021 · PMID 34041811 · validated civic_curation pubmed

Refractory infantile high-grade glioma containing TRK-fusion responds to larotrectinib.

· Pediatr Blood Cancer · 2021 · PMID 33403813 · validated civic_curation pubmed

Cribriform neuroepithelial tumor (CRINET): a nonrhabdoid ventricular tumor with INI1 loss and relatively favorable prognosis.

· J Neuropathol Exp Neurol · 2009 · PMID 19915490 · validated civic_curation pubmed

High-Resolution Genomic Analysis of Cribriform Neuroepithelial Tumors of the Central Nervous System.

· J Neuropathol Exp Neurol · 2015 · PMID 26352987 · validated civic_curation pubmed

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.

· Oncotarget · 2015 · PMID 26423602 · validated civic_curation pubmed

PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

· Cancer Res · 1997 · PMID 9331072 · validated civic_curation pubmed